What Researchers Did
The researchers tested whether hyperbaric oxygen treatment helped people with long-standing, stable multiple sclerosis (MS) by comparing it with a placebo in a double-blind trial.
What They Found
In this randomized, double-blind, placebo-controlled trial of 82 patients with chronic stable MS, hyperbaric oxygen therapy produced no significant difference from placebo on disability scores, magnetic resonance imaging, or evoked potentials. Forty-one patients received 20 consecutive daily treatments of 100% oxygen, followed by 7 booster treatments over the next 6 months. The other 41 patients received "air" (12.5% oxygen at 1.75 atmospheres absolute). The groups did not differ on the Extended Kurtzke Disability scores or Kurtzke Functional scores after the first 20 treatments or after the boosters. The authors concluded that hyperbaric oxygen is not effective in treating chronic stable MS.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract reports only patients with chronic stable MS, so the findings do not cover other types or stages of the disease, and it gives no details on side effects or on how long patients were followed after the booster treatments.